Literature DB >> 10685735

Helping patients with Crohn's disease quit smoking.

R J Hilsden1, D C Hodgins, A Timmer, L R Sutherland.   

Abstract

Smoking is not only a risk factor for Crohn's disease, but ongoing smoking is associated with a poorer disease course. Therefore, smoking cessation should be an important treatment strategy for Crohn's disease patients who smoke tobacco. Recent improvements in understanding how people quit smoking and the development of pharmacological interventions, such as nicotine patches and bupropion, have improved cessation rates. In this article, we first briefly review the evidence supporting the adverse effects of smoking on the disease course. We next review the current understanding of how people change addictive behaviors, such as smoking. We then describe how the gastroenterologist can aid the patient with Crohn's disease to quit smoking, including appropriate and brief counseling strategies and the use of adjunctive treatments. Given the improvements in smoking cessation strategies, all patients with Crohn's disease should be strongly advised to quit smoking and be aided in doing so.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10685735     DOI: 10.1111/j.1572-0241.2000.t01-1-01789.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  9 in total

1.  Factors affecting health related quality of life of patients with inflammatory bowel disease.

Authors:  Francesc Casellas; Josefa López-Vivancos; Alfonso Casado; Juan-Ramon Malagelada
Journal:  Qual Life Res       Date:  2002-12       Impact factor: 4.147

Review 2.  The impact of smoking in Crohn's disease: no smoke without fire.

Authors:  Marian C Aldhous; J Satsangi
Journal:  Frontline Gastroenterol       Date:  2010-09-23

Review 3.  Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cells.

Authors:  Lorise C Gahring; Scott W Rogers
Journal:  AAPS J       Date:  2006-01-13       Impact factor: 4.009

4.  Cytokine-induced alterations of α7 nicotinic receptor in colonic CD4 T cells mediate dichotomous response to nicotine in murine models of Th1/Th17- versus Th2-mediated colitis.

Authors:  Valentin Galitovskiy; Jing Qian; Alexander I Chernyavsky; Steve Marchenko; Vivian Gindi; Robert A Edwards; Sergei A Grando
Journal:  J Immunol       Date:  2011-07-22       Impact factor: 5.422

Review 5.  Anti-inflammatory effects of nicotine in obesity and ulcerative colitis.

Authors:  Shaheen E Lakhan; Annette Kirchgessner
Journal:  J Transl Med       Date:  2011-08-02       Impact factor: 5.531

Review 6.  The Neuromodulation of the Intestinal Immune System and Its Relevance in Inflammatory Bowel Disease.

Authors:  Martina Di Giovangiulio; Simon Verheijden; Goele Bosmans; Nathalie Stakenborg; Guy E Boeckxstaens; Gianluca Matteoli
Journal:  Front Immunol       Date:  2015-11-20       Impact factor: 7.561

7.  Anti-inflammatory effects of the nicotinergic peptides SLURP-1 and SLURP-2 on human intestinal epithelial cells and immunocytes.

Authors:  Alex I Chernyavsky; Valentin Galitovskiy; Igor B Shchepotin; Sergei A Grando
Journal:  Biomed Res Int       Date:  2014-05-04       Impact factor: 3.411

8.  The effect of a multidisciplinary approach for smoking cessation in patients with Crohn's disease: Results from an observational cohort study.

Authors:  Pierachille Santus; Dejan Radovanovic; Davide Raiteri; Stefano Pini; Giuseppe Spagnolo; Giovanni Maconi; Maurizio Rizzi
Journal:  Tob Induc Dis       Date:  2020-04-02       Impact factor: 2.600

9.  Effectiveness of a Telephone-Based Motivational Intervention for Smoking Cessation in Patients With Crohn Disease: A Randomized, Open-Label, Controlled Clinical Trial.

Authors:  Ester Navarro Correal; Francesc Casellas Jorda; Natalia Borruel Sainz; Virginia Robles Alonso; Claudia Herrera de Guise; Arantxa Ibarz Casas; Josep Maria Sánchez García; Genoveva Vila Morte; Carmen Fuentelsaz Gallego
Journal:  Gastroenterol Nurs       Date:  2021 Nov-Dec 01       Impact factor: 0.978

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.